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 A 1 ist of drugs which interfere with hemostasis is found 
in Appendix I. The largest number of reported cases of antibiotic-
3-22 
induced hemostatic defects is associated with carbenicil1 in, , and 
20 30 
penicillin G. ~ These hemostatic defects are identified primarily as 
platelet dysfunction with some cases resulting in clinical bleeding. 
20,29,30 30 29 17,31,32 
Ampicillin, methicil 1 in, oxacillin, cloxacillin, 
. . * n-i . 17,31,32 , _ . i • 20s28»29,33 . ~ _ « 34 . » . 
ticarcillin, cephalothin, and cefazolin show simi-
lar effects when these drugs are given to animals or humans prior to 
blood sampling for in vitro aggregation studies. This same dysfunction 
is thought to occur when normal platelet-rich plasma (PRP) is spiked 
with these drugs prior to aggregation studies. The exact mechanism of 
the effect on platelets is unknown. 
When a vessel is damaged, platelets adhere to the exposed elements 





® The hemostatic mechanism is initiated with platelet 
adhesion to the site of injury. After adhesion, aggregation of platelets 
to each other enlarges the hemostatic plug. Aggregation at the site of 
injury is facilitated by a number of stimuli. Adenosine diphosphate 
(ADP), released from damaged tissue, and collagen, released from exposed 
subendothelium, stimulate platelet aggregation. Epinephrine is present 
from catecholamine release during the vascular phase of injury and 
thrombin formation is present from activated coagulation proteins which 
contribute to the further activation of platelets. Primary aggregation 
results from direct stimulation of the platelet by the various stimuli. 
It is considered to be a reversible process. Platelets which aggregate 
may begin to disaggregate and recirculate throughout the rest of the 
body. Secondary aggregation, which follows primary aggregation, is 





tion of prostaglandin s y n t h e s i s R e l e a s e d ADP and prostaglandins 
further stimulate platelet aggregation and secretion.^ This process 
results in an irreversible aggregation of platelets. 
The activation of the extrinsic and intrinsic coagulation pathways 
results in activation of thrombin and the formation of fibrin.
36
 The 
fibrin formation within the platelet mass appears to stabilize the mass 
as a firm structure. At this point, no one mechanism is predominant; 
however, they all work together to form a stable clot. 
Platelet aggregation studies are used to identify platelet defects. 
When a proper physiologic stimulus (ADP, collagen, epinephrine) is added 
to PRP the aggregation response can be quantitated by the change in the 
optical density as the platelets aggregate. Not all laboratory identi-
fied platelet dysfunction results in clinical bleeding nor is there any 
in vitro test which correlates with the presence of clinical bleeding. 
Screening individuals with a bleeding time is presently the easiest way 
to detect altered platelet function, although this is not 1001 predic-
tive.
43
 Other patient factors such as individual sensitivities, under-
lying disease, trauma or surgery may predispose the patient to situa-
tions where altered platelet function may cause bleeding. 
The defect in platelet aggregation induced by antibiotics is more 
commonly seen with the use of ADP as the aggregating agent. Inhibition 
of the secondary wave of ADP-induced aggregation is initially observed. 
At higher concentrations of antibiotics, depression of the primary aggre-
1 Q 9'3 




The results of collagen and epinephrine-induced platelet aggrega-




>23,26,29,30,33 S o n i e r e p o r t s noted a 
marked inhibition of collagen-induced platelet aggregation. Other 
investigators did not find these results. The platelet response to epi-
nephrine is also variable. The demonstration of the loss of secondary 
aggregation without interference of primary aggregation is not consis-
tently seen. 
A review of the literature revealed some studies which did not 
demonstrate in vivo or in vitro changes when aggregation studies were 
Of] PI ftft 
performed. The reasons for these discrepancies may stem from 
4 - 8 1 8 
methodology variations in incubation times ' ' and in vivo contact 
Q 
times prior to sampling for platelet aggregation testing. Other dis-
crepancies are in the dosages of antibiotics used in vitro which are 
clinically unattainable and the concentrations of aggregating agents 
o ]A in op 




Penicillin-induced platelet dysfunction can be detected by pro-
longation of the bleeding time within 30 minutes to 3 days of starting 
therapy. Maximum platelet dysfunction in vivo can be identified by 
performing aggregation studies within 24 hours to 10 days after anti-
biotic administration, depending upon the dose of antibiotic and the 
concentration of aggregating agent. The duration of the dysfunction 













32,33 ancj m a y b e due to an irreversible effect on the platelet. 
Episodes of clinical bleeding, such as melena, wound oozing, and 
hemorrhage are reported with the use of high doses of carbenicillin , 
7,9,13,14,19 A N D P E N I C I N I N G. Nafcillin was recently associated with 
4 
these findings.* Two patients at the University of Utah Hospital 
who were treated with high doses of nafcillin showed clinical signs of 
bleeding which resolved upon discontinuation of the antibiotics. Plate-
let aggregation studies were performed on the first patient and showed 
marked inhibition of the secondary wave and depression of the primary 
aggregation response to ADP. After one month without drug administra-
tion, the aggregation studies returned to normal. The patient was re-
challenged with the same dose of antibiotic and demonstrated recurrence 
of the effects on the primary and secondary aggregation response. 
Nafcillin, a semisynthetic penicillin, is used as a first-line 
antibiotic for penicillin G resistant staphylococcal infections.45.46 
Only recently was nafcillin-induced platelet dysfunction noted. It has 
not been previously reported. Therefore, an initial study to investigate 
this problem was designed. 
OBJECTIVES 
To evaluate the effect of nafcillin on platelet aggregation. 
To investigate the effect of increasing concentrations of 
nafcillin on the aggregation response. 
METHODS 
Study Design 
This investigation utilized a controlled-paired, equi-
valent time sample design. Samples were matched for similar platelet 
count, volume, incubation time and temperature. In addition, the 
* Data on file at the University of Utah Coagulation Laboratory. 
5 
aggregating stimuli and duration of the experimental run-times were 
matched. 
The effect of increasing concentrations of nafcillin in PRP was 
compared to a control in PRP. Three different aggregating agents were 
used at 3 separate concentrations. The samples were run in duplicate 
for each concentration of the aggregating agent. (Set one.) The entire 
investigation was repeated 10 days later to ensure reproducibility. 
(Set two.) 
Preparation of the blood 
Blood was collected from 3 fasted, healthy volunteers (2 
men, 1 woman) who had not ingested aspirin or any other drugs which 
could alter normal platelet aggregation for at least 14 days prior to 
@ 
the blood draw. All tubes were sealed with Parafilm (American Can 
Co., Greenwich, Conn.) when not in use. 
Collection of blood. Blood was drawn in plastic collection 
tubes and gently mixed immediately with the appropriate anticoagulant 
(9 parts venous blood and 1 part 0.13 M sodium citrate). All collection 
equipment and transfer utensils were plastic or siliconized glassware 
to minimize mechanical activation of the platelets.
47 
Preparation of platelet-rich plasma and platelet-poor plasma 
(PPP). Fresh, room temperature, citrated whole blood was centrifuged 
at 205 g (930 RPM) for 12 minutes. The top layer of PRP was then 
transferred by plastic pipette to a second plastic tube. The citrated 
whole blood was respun at 5500 g (5,000 RPM) for 15 minutes. The plasma 
layer (PPP) was then transferred to a third plastic tube. The PRP from 
each volunteer was pooled in equal volume before standardization. The 
PPP was also pooled before standardization. 
6 
Standardization of the platelet-rich plasma. The platelet count 




 (Model ZBI, 
Coulter Electronics, Inc., Hialeah, Fla.). The platelet count in the 
final plasma was standardized by a mixture of PRP and PPP to obtain a 
platelet count of 250,000/mm
3
. The standardization technique is descri-
bed in Appendix II. 
Preparation of antibiotics 
Reconstitution and storage. Sodium nafcillin powder without 
preservatives (Wyeth Laboratories, West Chester, Penn.) was reconstitu-
ted and then diluted with Owrens buffer to final test concentrations. 
The technique used to prepare Owrens buffer is described in Appendix III. 
All concentrations of nafcill in were freshly prepared with Owrens buffer 
and the tubes discarded within 24 hours after reconstitution. 
Dilutions of antibiotic. After the antibiotic was reconsti-
tuted it was further diluted to final concentrations of 25, 50, 75, 100, 
200, and 1000 mcg/ml in PRP (spiked samples*). Dilutions were made 
according to the procedure outlined in Appendix IV. 
Confirmation of test antibiotic concentrations. Similar 
volumes of antibiotic were added to identical tubes of Owrens buffer to 
achieve final concentrations of 25, 50, 75, 100, 200, and 1000 mcg/ml. 
After adequate mixing, a 2 ml aliquot was pipetted into another plastic 
tube and frozen at -70° C until assayed. These final antibiotic concen-
trations were assayed microbiologically by the modified method of 
50 
Bennett et al, using Sarcinia lutae as the test organism. 
Preparation of aggregating agents 
Aggregating agents were prepared according to the policy and 
* Spiked samples refer to PRP to which nafcillin has been added. 
7 
procedures of the Coagulation Laboratory at the University of Utah 
Hospital. These methods are described in Appendix V. Stock solutions 
of ADP and collagen were freshly prepared each month and frozen at -70° C. 
Immediately before use, these preparations were thawed and diluted to 
give the working solutions of ADP and collagen. Dilutions of epineph-
rine were freshly prepared from a commercially available product. 
Standard aggregation response curves of all reagents were recorded. Di-
lute solutions of ADP, epinephrine, and collagen were discarded after 
each run. 
Adenosine Diphosphate. ADP (Sigma Laboratories, St. Louis, 
Mo.) was used in final concentrations of 3 x 10"
6
 M, 1 x 10"
5




Epinephrine. Epinephrine (Parke Davis, Detroit, Mi.) was 
used in final concentrations of 1 x 10"
5
 M, 1 x 10"
5
 M, and 1 x 10"
4
 M. 
Collagen. Crude collagen extract (Sigma Laboratories, St. 
52 53 
Louis, Mo.) was prepared by a method of Day and Holmsen ' and stored 
at -70° C until used. Immediately before use, the collagen solution 
was thawed, rehomogenized and kept at 4° C (ice bath) during the 
experiment. A standard response curve was prepared by the addition of 
diluted collagen to PRP until adequate aggregation was demonstrated. 
Dilutions of this solution were made with 1.67 mM acetic acid to final 
ratios of 1:8, 1:16, 1:32, and 1:64. 
Aggregation studies 
Aggregation studies were performed using the instruments and 
supplies in the Coagulation Laboratory at the University of Utah 
Hospital. 
8 
Method. Aggregation studies were performed by the turbido-
metric m e t h o d
5 2 - 5 5





Corp., Broomall, Penn.). Platelet-poor plasma was used as a standard of 
the maximum change in optical density. Aggregating agents were added 
to PRP spiked with nafcillin and control PRP to which Owrens buffer was 
added. Recordings of the change in optical density were made on a dual 
channel recorder (Linear Instruments Corp., Irvine, Calif.) outfitted 
with 10 inch chart paper. All aggregation studies were done in dupli-
cate. 
Incubation. Spiked and control samples of PRP were incu-
bated for 1.5 hours at 37° C in a water bath. 
DATA ANALYSIS 
Calculations 
Calculations of the percent response was done by equation 
#1. 
sample optical density change 1 0 0 = 56 response (eq. 1) 
total optical density change 
The percent response for both the control and spiked samples were cal-
culated by this method. The percent response (mean ± S.E.M.*) was 
determined from the duplicate runs. 
Hypothesis and data analysis 
Null hypothesis: There is no difference in the percent 
response. If they do not vary significantly, then it is assumed that 
nafcill in, in the measured concentrations., does not influence platelet 
aggregation in vitro. Probability (pj values of less than 0.05 were 
* S.E.M. - Standard Error of the Mean 
9 
considered significant. Mathematical computations were performed on 
D 
a Hewlett-Packard (HP67) programmable calculator (Hewlett Packard Co., 
Corvallis, Or.). Statistical testing of the hypothesis was performed by 
analysis of variance (ANOVA).^ 
RESULTS 
Collagen 
No inhibition of platelet aggregation in control or 
spiked samples was observed with nafcillin concentrations ranging from 
25-200 mcg/ml (Table 1,2). There was a significant difference between 
control and spiked samples at 1000 mcg/ml (Table 1). Significant inhi-
bition of the maximum aggregation response was shown with resultant 
disaggregation of the samples at weak dilutions of collagen (Figure 1). 
In set one, this effect occurred at a collagen dilution of 1:32 and in 
set two it occurred at a collagen dilution of 1:64 (Table 2). The 
difference between the results of the two sets can be explained by the 
variability in the preparation of the collagen suspensions and not 
directly to the influence of the drug. 
Epinephrine 
No significant inhibition of platelet aggregation in 
the control or spiked samples was observed (Table 3, 4). Weak concen-
trations of epinephrine (1 x 10~
6
 M) consistently showed a poor response 
and in many cases demonstrated a severely depressed secondary wave form 
in both the spiked and control samples. This effect could not be 
attributed to the drug because it could be shown in both the control and 
spiked samples. Duplication of the sample response for each concen-
tration of epinephrine demonstrated a reproducible response (Table 4). 
10 
Adenosine Diphosphate 
No significant inhibition of platelet aggregation in 
control or spiked samples was observed at nafcillin concentrations 
ranging from 25-200 mcg/ml (Table 5, 6). At nafcill in concentrations of 
100 mcg/ml and 200 mcg/ml, the aggregation response to weak ADP (3 x 
10-
6
 M) showed a prominent secondary wave form which did not appear in 
the control samples (Figure 2, 3). Significant inhibition of the 
secondary wave and depression of the primary response to weak ADP (3 x 
10"
6
 M) was shown in nafcillin spiked PRP at 1000 mcg/ml (Table 7 , 8 ) . 
This effect did not occur in the control samples (Figure 4). Duplication 
of the sample response for each concentration of ADP demonstrated re-
producibility (Table 8). 
The pH of the control and spiked PRP samples did not 
exceed the pH of 8.0 for the duration of the aggregation studies. The 
pH of the spiked PRP was usually 0.2 pH units below that recorded for 
the control samples. 
Antibiotic concentration 
Final antibiotic concentrations were verified for both 
sets of trials by microbiological assay. The percent recovery of naf-
cillin-spiked samples ranged from 76-133$. 
DISCUSSION 
Hemostasis 
The human platelet, numbering approximately 200,000 to 
400,000 per cubic millimeter, has a life span of 8-10 days. They cir-
culate as smooth, disc-shaped cells that are non-adherent to each other 
n 
36 37 47 
arid normal endothelium. ' ' The interaction of the vessel wall, 
platelet and coagulation proteins is important in normal hemostasis. 
The primary goal of these interactions is to arrest bleeding at the site 
of injury. When a vessel is damaged, the hemostatic mechanisms are 
initiated with platelet adhesion to the site of injury. After adhesion, 
aggregation of platelets to each other enlarges the hemostatic plug. 
The platelet plug plays an important role in the maintenance of 
hemostasis. Defective adhesion, aggregation or secretion may result in 
a poorly formed platelet plug. This may result in a bleeding diathesis 
associated with clinically evident bleeding, i.e. petechiae, wound 
oozing and hemorrhage. When a bleeding disorder is suspected, in 
vitro platelet aggregation studies are useful to determine whether 
platelet dysfunction is contributing to the bleeding disorder. Platelet 
aggregation using a number of exogenously added stimuli has advanced our 
knowledge of platelet physiology and subsequently our understanding of 
the pathophysiology of many platelet disorders. Aggregating agents 
which stimulate the platelet by different mechanisms can be used to 
identify the platelet defect. 
Aggregation studies 
The results of this study demonstrate that nafcill in 
results in platelet dysfunction which is similar to that found with 
•3 nn 20 28-30 34 
other penicillins and cephalosporins. ' ' Significant inhi-
hibition of the aggregation response to weak concentrations of ADP was 
found with large concentrations of nafcillin (Table 7). This finding is 
the most consistently reported platelet abnormality in the literature 
for other penicillins and cephalosporins. The presence of a prominent sec-
ondary aggregation was observed in the spiked samples at 100 mcg/ml and 
12 
200 mcg/ml of nafcillin with weak ADP (3 x 10"
6
 M) (Figure 2, 3). This 
effect did not occur in the control samples. These effects were observed 
without altering the maximum aggregation response. The presence of the 
secondary wave usually results from the stimulation of platelets with 
a weak aggregating agent. This observation was important because 
nafcillin appears to diminish the effect of ADP on the platelet. The 
use of weaker concentrations of ADP can show a significant platelet 
dysfunction at lower antibiotic concentrations. 
Abnormal collagen stimulated aggregation was demonstrated at high 
nafcillin concentrations. This effect is not consistently reported in 









Significant inhibition of the aggregation response to weak dilutions of 
collagen occurred in PRP spiked with 1000 mcg/ml of nafcillin (Table 1). 
The collagen dilution producing this effect differed between set one 
and set two. The reason for this difference is probably due to the 
method of preparation of the aggregating agent. Significant inhibition 
in set one was shown at a dilution of 1:32 in the spiked samples. At 
dilutions of 1:64, neither spiked nor control samples responded. The 
aggregating stimulus was so weak that neither sample responded. Sig-
nificant inhibition in set two occurred at a dilution of 1:64. Most of 
the published literature reports the aggregation of platelets with only 
one dilution of collagen. The use of this technique probably contributed 
to the higher antibiotic requirement before the effect was demonstrated. 
No conclusion could be made from the results of the epinephrine 
stimulated platelet aggregation. Many of the results are inconsistent 
(Table 3, 4). Epinephrine is usually added to PRP last because the 
platelet responsiveness improves with t i m e
5 7










 and thereafter declines. The lack of consistent results 
was probably related to the time factor and decreased platelet respon-
siveness. In this study the addition of epinephrine did not begin 
until approximately 2.5 hours after venipuncture. As with collagen, in-
8 in 
consistent findings with epinephrine were found in the literature. ' 
29-33 
In vitro reproduction of nafcil1 in-induced platelet dysfunction 
requires many times the plasma concentrations that can be achieved 
Q in 
clinically. This disparity is well recognized with carbenicil1 in 
and penicillin g,23,26,29 j | i e r e f o r e s either prolonged contact time 
with the antibiotic or a metabolite may be involved in this inhibition. 
Possibly some unrecognized plasma factor may be required. 
The role of the incubation period is still unclear. Lederer et 
Q 
al studied the aggregation of PRP to which carbenicil!in had been 
added in vitro. They found that carbenicil 1 in had no immediate effect; 
but, after two hours of incubation at 37° C, platelet aggregation to 
ADP (2 x 10"
6
 M) was inhibited. In contrast, Shattil et al
6 3
 found an 
immediate effect with carbenicil1 in and penicillin in PRP when aggre-
gated with ADP (2 x 10~
6
 M). The reason for this disparity is unclear. 
Mechanism 
The mechanism of the nafcillin-induced platelet dys-
function is unknown. Platelet adhesion, aggregation and secretion are 
decreased with penicillin G and carbenicil1 in. Similar effects on 
platelet aggregation were noted with nafcillin.* The results of this 
study are in agreement with these findings. 
Cazenave et al
2 6
 postulated that these antibiotics coat the plate-
let surface and interfere with membrane receptor activation, although 
actual binding of penicillin to platelets is not yet demonstrated. 
Shattil et al
6 3
 found that epinephrine and ADP were competitively inhi-
bited at membrane receptors by large doses of carbenicill in and penicillin. 
These antibiotics decreased the affinity of epinephrine to ^-adrenergic 
receptors and inhibited the covalent incorporation of an ADP analogue 
into a platelet membrane polypeptide which may be the ADP receptor. 
Penicillins are bound to a variable extent to plasma proteins,
64 
65 
bacterial membrane proteins ,and the membrane proteins of the red 
blood cells.
6
® Padfield et al®
7
 showed that penicillin G was highly 
bound to a number of phospholipids in vitro. Ampicillin was shown to 
be bound much less than penicillin G. Many of these phospholipids are 
identified in the outer platelet membrane.
40
 Since platelet membranes 
also contain glycoproteins
68
 that are irregularly distributed on the 
surface, further work is needed to determine the penicillin binding 
characteristics to platelet proteins and phospholipids. 
Little is known about the entire sequence of cellular events that 
follow agonist binding but many critical details of the platelet reaction 
were elucidated in recent years.
6 9
 After the initial activation of the 
platelet, it will undergo shape change and centralization of the cyto-
plasmic organelles. These phenomena are related to the activation of 
contractile proteins by increased cytoplasmic calcium. These contractile 
* Data on file at the University of Utah Coagulation Laboratory. 
15 
proteins resemble actin and myosin which are found in other cells. The 
processes which activate and control the contractile mechanism are not 
well defined. 
The stimulation of the platelet membrane receptor activates phospho-
lipase enzymes to release arachidonic acid from membrane phospholipids. 
Arachidonic acid is converted to cyclic endoperoxides which are further 
converted to thromboxane It is now hypothesized that these 
products of prostaglandin synthesis may be involved in the iontophoretic 





calcium in the cytoplasm initiates the activation of the contractile 
proteins and release of the subcellular organelles. Recently Johnson 
et a l
7 2
 reported that carbenicil1 in does not affect prostaglandin 
synthesis. Therefore, the mechanism by which penicillin produces this 
platelet defect remains unknown. Further investigations are warranted 
to define this mechanism. 
Evaluation 
The clinical importance of these effects on platelets 
is unclear at this time. Clinically evident bleeding was observed in 
two patients receiving large doses of nafcillin.* Results of platelet 
aggregation studies performed at that time revealed a nafcillin-induced 
platelet dysfunction. Similar effects on platelet aggregation were 
shown in this study. Not all patients who receive large doses of nafcillin 
will demonstrate clinically evident bleeding but they may show altered 
platelet function. The hemostatic defect may be accentuated by the 
patients'underlying disease states or other drugs. The altered platelet 
* Data on file at the University of Utah Coagulation Laboratory. 
function may predispose them to bleeding. Further study to investi-
gate the in vivo effects of nafcil1 in is warranted. Identification of 
the plasma concentration, time of onset, and duration of the effect is 
important information to determine the clinical significance of this 
adverse effect. 
CONCLUSION 
Platelet dysfunction was shown when large concentrations of 
nafcil 1 in were incubated with PRP for 1.5 hours when compared to con-
trol. Significant inhibition of the aggregation response to weak con-
centrations of the ADP and collagen were shown in spiked samples at 
1000 mcg/ml of nafcillin. Depression of the secondary wave was demon-
strated with low concentrations of ADP in spiked samples beginning at 
100 mcg/ml of nafcillin. The clinical significance of this study 
cannot be interpreted at this time. Further study to evaluate these 
effects on platelets in vivo is warranted. 
Table - Raw Data. oae-Induced Platelet Aggregation. Control and Nafcillin-Spiked Samples. 
Nafcillin Final Percent of Maximum Aggregation 
Concentration Collagen * 
(spiked) Dilution Control Spiked p value® Control Spiked p value 
25 mcg/ml 1:8 83. 8 85.0 78. 8 82. 7 NS 76. 8 80. 2 80. 0 78. 8 NS 
1:16 78. 0 85.0 81. 3 83. 8 28. 4 21. 2 20. 0 20. 0 
1:32 75. 9 79.3 76. 5 75. 3 ND
C 
ND ND ND 
1:64 42. 5 40.0 35. 0 37. 5 ND ND ND ND 
50 mcg/ml 1:8 78. 8 80.0 85. 2 81. 3 NS 84. 0 78. 0 86. 3 82. 7 NS 
1:16 73. 8 75.3 77. 5 78. 8 80. 0 87. 5 82. 5 81. 3 
1:32 28. 8 26.3 25. 9 25. 0 85. 0 81. 3 83. 8 80. 0 
1:64 ND ND ND ND 57. 5 72. 5 63. 8 66. 3 
75 mcg/ml 1:8 82. 5 82.5 82. 5 82. 5 NS 75. 6 77. 5 80. 0 80. 0 NS 
1:16 78. 8 73.8 80. 2 77. 8 81. 3 78. 8 78. 8 77. 5 
1:32 68. 8 65.0 65. 9 65. 0 77. 5 76. 3 77. 5 83. 8 
1:64 17. 5 20.0 20. 0 20. 7 72. 5 71. 3 72. 5 70. 0 
a Statistical analysis done by analysis of variance, significance p < 0.05. 
b NS - Not Significant 
c ND - Not Determined 
Table Raw Data. oae-Induced Platelet Aggregation. Control and Nafcillin-Spiked Samples 
Nafcillin Final Percent of Maximum Aggregation 
Concentration Collagen — — 
(spiked) Dilution Control Spiked p value
3
 Control Spiked p value 
100 mcg/ml 1 8 77.2 80.0 79.0 70.4 NS
b 
86.3 86.3 83.8 85.0 NS 
1 16 72.5 74.1 77.8 76.3 82.5 82.5 81.3 85.0 
1 32 22.5 17.5 21.5 21.0 80.0 81.5 83.8 75.3 
1 64 ND
C 
ND ND ND 77.5 76.3 76.3 75.3 
200 mcg/ml 1 8 80.0 81.3 82.7 ND NS 83.1 79.0 82.5 83.8 NS 
1 16 76.3 80.0 86.3 81.3 77.8 82.7 82.5 82.5 
1 32 55.0 53.8 55.0 61.3 77,5 80.0 81.3 81.3 
1 64 20.0 22.5 22.5 22.2 72.5 72.5 77.5 72.5 




































a Statistical analysis done by analysis of variance, significance p < 0.05. 
b NS - Not Significant 
c ND - Not Determined _. 
CO 
Table - e n oae-Induced Platelet Aggregation. Control and Nafcilin-Spiked Samples. 






(spiked) Dilution Control Spiked Control Spiked 
25 mcg/ml 1:8 84.4 + 0.6 80.8 + 2.0 78.5 ± 1.7 79.4 
1:16 81.5 + 3.5 82.6 ± 1.3 24.8 + 3.6 20.0 
1:32 77.6 + 1.7 75.9 ± 0.6 ND
C 




50 mcg/ml 1:8 79.4 ± 0.6 83.3 ± 2.0 81.0 ± 3.0 84.5 + 1.8 
1:16 74.6 ± 0.8 78.2 ± 0.7 83.8 + 3.8 81.9 + 0.6 
1:32 27.6 ± 1.3 25.5 ± 0.5 83.2 ± 1.9 81.9 + 1.9 
1:64 ND ND 65.0 ± 7.5 66.6 ± 0.3 
75 mcg/ml 1:8 82.5 + 0.0 82.5 ± 0.0 76.6 + 1.0 80.0 + 
1:16 76.3 + 2.5 79.0 + 1.2 80.1 + 1.3 78.2 + 
1:32 66.9 ± 1.9 65.5 + 0.5 76.9 ± 0.6 80.7 + 
1:64 18.8 + 1.3 20.4 ± 0.4 71.9 + 0.6 71.3 + 
a Number of Observations (2) 
b Standard Error of the Mean 
c ND - Not Determined 
Table t e n oae-Induced Platelet Aggregation. Control and Nafcillin-Spiked Samples. 











78.6 ± 1.4 
73.3 ± 0.8 
20.0 ± 2.5 
NDC 
74.7 ± 4.3 
77.1 ± 0.8 
21.3 ± 0.3 
ND 
86. 3 + 0.0 84. 4 + 0 .6 
82. 5 + 0.0 83. 2 + 1 .9 
80. 8 ± 0.8 82. 7 + 1 .2 
76. 9 + 0.6 75. 8 ± 0 .5 
200 mcg/ml 1 :8 85.7 + 4.4 
1 :16 78.2 + 1.9 
1 :32 54.4 + 0.6 
1 :64 21.3 + 1.3 
82.7 + 0.0
d 
81.1 ± 2.1 83.2 + 
83.8 + 2.5 80.3 + 2.5 82.5 + 
58.2 + 3.2 78.8 + 1.3 81.3 ± 
22.4 + 0.2 72.5 ± 0.0 75.0 + 
1000 mcg/ml 1:8 83.3 + 1.3 85.7 + 0.7 85.7 + 0.7 86.9 ± 
1:16 83.8 + 0.0 77.9 + 0.1 81.6 + 1.1 79.4 ± 
1:32 80.0 ± 0.0 41.3 + 1.3 83.2 ± 1.9 79.4 + 
1:64 23.8 ± 1.3 21.3 + 0.0 82.6 + 1.3 39.4 + 
a Number of Observations (2) 
b Standard Error of the Mean 
c ND - Not Determined 
d Single Value Only 







Percent of Maximum Aggregation 
Spiked p value® Control Spiked p value 
25 mcg/ml 1 x 10"
4 
77.8 76.3 53.8 54.4 NS
b 
78.0 80.0 85.0 80.0 NS 
1 x 10-f 76.3 76.3 75.3 75.3 86.4 80.5 85.0 80.0 
1 x 10"
6 
26.8 26*3 37.5 35.0 45.0 35.0 52.5 57.5 



























































a Statistical analysis done by analysis of variance, significance p < 0.05. 
b NS - Not Significant 
Table Raw Data. inephe-Induced Platelet Aggregation. Control and Nafcillin-Spiked Samples. 
Nafcillin Final Epinephrine Percent of Maximum Aggregation 
Concentration Concentration 
(spiked) (M) Control Spiked p value
3
 Control Spiked p value 
100 mcg/ml 1 X 10' -4 
r-
76. .3 76, .3 76. .3 63, ,0 NS
b 
83, .8 80 .0 78, .8 NC i
c 
NS 
1 X 10' -5 77. .5 76. .3 73, ,8 76, .3 81 .3 80 .2 81, .3 78. 8 
1 X io--6 63, .8 47. .5 25, .0 27, .5 37, .0 30 .0 76, .3 77. 5 
200 mcg/ml 1 X 10" 
.4 
48, .8 53. .8 67. ,9 60, .0 NS 78, .8 73 .4 80. .0 78. 8 NS 
1 X 10* -5 73. .8 65. .0 73, .8 72, .8 77, .5 80 .0 80. .0 81. 3 
1 X 10" -6 32. .5 33. .8 31, ,3 31. .3 67. .5 52 .5 73, .8 68. 8 

















NS 82.5 81.3 78.8 77.5 
81.3 82.7 83.8 84.0 
52.5 38.8 35.4 36.3 
NS 
a Statistical analysis done by analysis of variance, signifiance p < 0.05. 
b NS - Not Significant 
c ND - Not Determined 
INS 
ro 
Table - e n i n e p h e - I n d u c e d Platelet Aggregation. Control and Nafcillin-Spiked Samples. 
Nafcillin Final Epinephrine Percent of Maximum Aggregation (Mean
3
 ± S.E.M. ) 
Concentration Concentration 
(spiked) (M) Control Spiked Control Spiked 
25 mcg/ml 1 X lO"
4 
77.1 + 0.8 54.1 + 0.3 79.0 + 1.0 88.5 ± 2.5 
1 X 10"
5 
76.3 + 0.0 75.9 + 0.6 83.5 + 3.0 82.5 ± 2.5 
1 X 1 0 - 6 26.6 + 0.3 36.3 
+ 1.3 40.0 + 5.0 55.0 + 2.5 
50 mcg/ml 1 X 10~
4 
57.6 ± 8.8 75.7 + 1.9 79.4 + 0.6 79.4 + 1.9 
1 X 10~
5 
74.9 ± 0.2 76.9 + 1.9 81.4 + 1.4 79.4 + 0.6 
1 X 1 0 - 6 29.6 + 0.5 30.3 ± 0.7 77.5 ± 2.5 75.7 + 3.2 
75 mcg/ml 1 X 1 0 - 4 71.4 ± 1.4 61.8 + 0.1 77.6 + 1.3 76.3 + 1.3 
1 X lO"
5 
77.6 ± 1.3 74.9 + 1.1 75.1 + 1.3 77.4 + 1.3 
1 X 10"
6 
26.0 + 1.5 28.5 + 0.8 73.2 + 0.7 73.2 + 0.7 
a Number of Observations (2) 
b Standard Error of the Mean 
ro 
CO 
Table t e n i n e p h e - I n d u c e d Platelet Aggregation. Control and Nafcillin-Spiked Samples. 






(spiked) (M) Control Spiked Control Spiked 
100 mcg/ml 1 X 1 0
1 
76.3 + 0.0 69.7 ± 6.7 81.9 + 1.9 78.8 + 0.0
C 
1 X 10"5 76.9 + 0.6 75.1 + 1.3 80.8 + 0.6 80.1 + 1.3 
1 X 10 55.7 + 8.2 26.3 + 1.3 33.5 + 3.5 76.9 + 0.6 
200 mcg/ml 1 X io-
4 
51.3 + 2.5 
1 X lO"
5 
69.4 + 4.4 
1 X 10-6 33.2 + 0.7 
64.0 + 4.0 76.1 + 2.7 79.4 + 0.6 
73.3 + 0.5 78.8 + 1.3 80.7 ± 0.7 
31.3 + 0.0 60.0 + 0.0 71.3 + 2.5 
1000 mcg/ml 1 x 10"
4
 70.2 ± 2.7 




 38.2 ± 1.9 
30.7 + 0.7 81.9 ± 0.6 78. 2 ± 0.7 
55.7 + 4.4 82.0 ± 0.7 83. 9 ± 0.1 
31.0 + 0.0 45.7 ± 6.9 35. 9 ± 0.5 
a Number of Observations (2) 
b Standard Error of the Mean 
c Single Value Only 
Table 5 - Raw Data. Adenosine Diphosphate (ADP)-Induced Platelet Aggregation. Control and Nafcillin-
Spiked Samples. 
Nafcillin Final ADP Percent of Maximum Aggregation 
Concentration Concentration 
(spiked) (M) Control Spiked p value
a
 Control Spiked p value 
25 mcg/ml 1 X 1 0
1 
82.5 81.0 78.8 72.5 NS
b 
88.5 79.5 85.2 88, ,8 NS 
1 X 10"
5 
76.5 77.5 76.3 83.8 78.3 83.8 83.8 85, .0 
3 X 10"
6 
59.3 52.5 63.8 58.8 75.0 73.8 59.4 70, .4 
50 mcg/ml 1 X 1 0 i 83.8 82.5 85.0 82.5 NS 82.5 83.8 82.5 85.0 NS 
1 X lO"
5 
76.8 76.5 85.2 81.5 82.5 77.5 78.8 78.8 
3 X 1 0 - 6 70.4 61.3 70.4 67.1 76.3 80.0 75.0 80.0 
75 mcg/ml 1 X 10~
4 
80.0 80.0 77.4 77.4 NS 76.3 80.0 81 .3 77.5 NS 
1 X lO"
5 
81.3 78.8 75.9 78.6 78.8 76.3 76 .3 78.8 
3 X 10-6 70.9 63.0 69.0 58.1 77.5 73.8 71 .3 73.8 
a Statistical analysis done by analysis of variance, significance p < 0.05. 
b NS - Not Significant 
Table 5 (Cont) - Raw Data. Adenosine Diphosphate (ADP)-Induced Platelet Aggregation. Control and 
Nafcillin-Spiked Samples. 
Nafcillin Final ADP Percent of Maximum Aggregation 
Concentration Concentration 
(spiked) (M) Control Spiked p value
3
 Control Spiked p value 
100 mcg/ml 1 X 10~
4 
76.3 77.5 80.2 80.0 NS
b 
82.5 87.5 80.0 85.0 NS 
1 X lO-f 75.0 75.0 78.0 79.0 83.1 87.5 85.0 76.3 
3 X 10-6 72.5 67.5 66.3 65.0 77.5 76.5 70.0 76.3 
200 mcg/ml 1 X 1 0
- 4 
80.0 91.3 82.5 80.0 NS 80.0 76.3 80.0 82.5 NS 
1 X 1 0 - 5 78.8 78.8 82.5 80.0 82.5 80.0 82.5 80.0 
3 X 1 0 - 6 62.5 70.0 65.0 63.8 80.0 77.5 77.5 78.8 
1000 mcg/ml x 10" 
x 10" 
x 10" 
See Table 7 See Table 7 
a Statistical analysis done by analysis of variance, significance p < 0.05. 
b NS - Not Significant. 
Table - a Adenosine Diphosphate (ADP)-Induced Platelet Aggregation. Control and Nafcillin-Spiked Samples. 






(spiked) (M) Control Spi ked Control Spiked 
25 mcg/ml 1 X 10-
4 
81.8 ± 0.8 75.7 ± 3.2 84.0 + 4.5 87.0 + 1.8 
1 X 10"5 77.0 ± 0.5 80.1 + 3.8 81.1 + 2.8 84.4 + 0.6 
3 X 10"
6 
55.9 ± 3.4 61.3 + 2.5 74.4 + 0.6 64.9 ± 5.5 
50 mcg/ml 1 X lO"
4 
• 2 + 0.7 83.8 + 1.3 83.2 ± 0.7 83.8 ± 1.3 
1 X lO"
5 
76.7 ± 0.2 83.4 ± 1.9 80.0 + 2.5 78.8 + 0.0 
3 X 10"
6 
65.9 ± 4.6 68.8 ± 1.7 78.2 ± 1.9 77.5 + 2.5 
75 mcg/ml 1 X 80.0 ± 0.0 77.4 + 0.0 78.2 ± 1.9 79.4 + 1.9 
1 X TO"
5 
80.1 ± 1.3 77.3 + 1.4 77.6 + 1.3 77.6 ± 1.3 
3 X 10~
6 
67.0 ± 4.0 63.6 + 5.5 75.7 + 1.9 72.6 ± 1.3 
a Number of Observations (2) 
b Standard Error of the Mean 








Percent of Maximum Aggregation (Mean
3
 ± S.E, 
Control Spiked Control Spiked 
1 0 0 mcg/ml 1 X 101 76.9 + 0.5 80.1 + 0.1 85.0 ± 2.5 82.5 + 1 X 75.0 + 0.0 78.5 ± 0.5 85.3 ± 2.2 80.7 + 
3 X 10"
6 
70.0 + 2.5 65.7 + 0.7
C 




200 mcg/ml 1 x 10-J 




85.7 + 5.7 81.3 + 1.3 78.2 + 1 .9 81.3 + 1.3 
78.8 + 0.0 81.3 + 1.3 81.3 + 1 .3 81.3 + 1.3 
66.3 ± 3.8 64.4 + Q.6
C 
78.8 + 1 .3 78.2 + 0.7
! 
1000 mcg/ml 1 X 1 0 ~ 4 
1 X TO"
5 
See Table 8 
3 X 10-6 
a Number of Observations (2) 
b Standard Error of the Mean 
c Depressed Secondary Wave 
ro 
00 
Table 7 - Raw Data. Adenosine Diphosphate {ADP)-Induced Platelet Aggregation. Control and Nafcillin-Spiked (1000 mcg/ml) Samples. 
ADP Percent of Maximum Aggregation 
Concentration — 
(M) Control Spiked p value® Control Spiked p value Control Spiked p value 
1 x 10"
4
 83.8 83.8 78.0 80.2 <0.001 82.5 81.3 85.0 86.3 <0,001 75.3 80.0 82.5 ND
b
 <0.001 
1 x 10"! 85.0 82.5 77.4 80.0 82.7 82.5 82.5 78.8 78.3 76.3 73.8 75.3 
3 x 10"
6
 77.8 72.5 55.6 49.4 80.0 82.5 48.8 51.3 76.3 73.8 49.4 48.8 
a Statistical analysis done by analysis of variance, significance p < 0.05. 
b ND - Not Determined. 
r\j 
U3 
Table 8 - Mean Adenosine Diphosphate (ADP)-Induced Platelet Aggregation. Control and Nafcillin-Spiked 
(1000 mcg/ml) Samples. 
a b 
ADP Percent of Maximum Aggregation (Mean
 ±
 S.E.M. ) 
Concentration 
(M) Control Spiked Control Spiked Control Spiked 
1 X 1 0
 5 
83.8 + 0.0 79.1 
1 X 
1 0
 c 83.8 + 0.7 78.7 
3 X 10"
6 
75.2 + 2.7 52.5 
±1.1 81.9 ± 0.6 85.7 
± 1.3
C
 82.6 ± 0.1 80.7 
± 3.1° 81.3 ± 1.3 50.1 
± 0.7 77. 7 ± 2 .4 82. .5 + J 0.0 
+ 1,9
C 




75. 1 + 1 .3 49. ,1 ± 0.3
C 
a Number of Observations (2) 
b Standard Error of the Mean 
c Depressed Secondary Wave 






Figure 1 - Platelet Aggregation Response to Collagen. 
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Figure 2 - Platelet Aggregation Response to Adenosine Diphosphate (ADP). 
Nafcillin-Spiked (100 mcg/ml) and Control Samples. 
33 
TIME (minutes) 
Figure 3 - Platelet Aggregation Response to Adenosine Diphosphate (ADP). 
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Figure 4 - Platelet Aggregation Response to Adenosine Diphosphate (ADP). 

















































* Collected from references #1, 2 
APPENDIX II 
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STANDARDIZATION OF PLATELET-RICH PLASMA (PRP) 
3 
Platelet concentrations were adjusted to 250,000/mm by diluting 
PRP with the corresponding platelet-poor plasma (PPP). Platelet 
count of the PRP was determined by the Coulter Counter^, Model ZBI, 
49 
then total count correlated by predetermined table provided by the 
company. Standardization was calculated by equations #1-3. 
standard count needed* x total volume of standardized _ j, , P R P , » 
actual count measured* PRP required "
 1 q ff } 
* number of platelets/mm
3 
Total volume of standardized PRP required - # mis PRP = 
# mis of PPP required for dilution (eq #2) 
Amount of PPP required for dilution - # mis of antibiotic (eq #3) 
or control solution 
to be added = 
actual # mis PPP to be added for 
standardization 
APPENDIX III 
PREPARATION OF OWRENS BUFFER SOLUTION 
Weigh 5.87 Gm. Sodium di-ethylbarbiturate. 
M.W. 207.2 
Weight 7.335 Gm. Sodium chloride. M.W. 58.5 
Dissolve both compounds in approximately 700 ml of deionized 
water. 
Add approximately 150 ml of 0.1 N Hydrochloric acid. 
Titrate to a pH of 7.35 with additional 0.1 N Hydrochloric 
acid. 
Add sufficient deionized water to make 1000 ml total volume. 
Store at 4° C. 
This solution was made fresh monthly. 
APPENDIX IV 
DILUTION OF NAFCILLIN 
Nafcillin monohydrate sodium (Wyeth Laboratories, West Chester, 
Pennsylvania), preservative-free powder was used. 
Lot # W802416 Expiration Date: August 1983 
Concentration, 889 meg of nafcillin base per 1 mg sodium nafcill in 
All dilutions were made with Owrens buffer and adequate mixing. Final 
concentrations of antibiotic used were 25, 50, 75, 100, 200, and 
1000 mcg/ml. 
1. Working solution: 25 mcg/ml in final concentration. 
Weigh* 101.2 mg of nafcillin powder and dilute to 9 ml with 
Owrens buffer. Then take 1 ml (10,000 meg) of above mixture 
and further dilute with 9 ml of Owrens buffer to get a 
concentration of 1000 mcg/ml. 
Pipette 0.35 ml and add to platelet-rich plasma (PRP) to 
make final concentration of 25 mcg/ml. 
350 mcg/14 ml = 25 mcg/ml. 
2. Working solution: 50 mcg/ml in final concentration. 
Weigh* 202.2 mg of powder and dilute to 9 ml with Owrens 
buffer. Then take 1 ml (20,000 meg) of above mixture and 
further dilute with 9 ml Owrens buffer to get a concentration 
of 2000 mcg/ml. 
Pipette 0.35 ml and add to PRP to make a final concentration 
of 50 mcg/nll. 
700 mcg/14ml = 50 mcg/ml . 
* All weights were measured with a Mettler Balance, Mettler Instrument 
Corp., Hightstown, N.J., Model H51AR. 
43 
3. Working solution: 75 mcg/ml in final concentration. 
Pipette 0.53 ml of solution in #2 (20,000 mcg/ml) and add to 
PRP to make final concentration of 75 mcg/ml. 
1060 mcg/14 ml - 75.7 mcg/ml. 
4. Working solution: 100 mcg/ml in final concentration. 
Weigh* 202.2 mg of powder and dilute to 9.0 ml with Owrens 
buffer. Then take 1 ml (20,000 meg) of above mixture and 
further dilute with 4 ml Owrens buffer to get a concentration 
of 4000 mcg/ml. 
Pipette 0.35 ml and add to PRP to make a final concentration 
of 100 mcg/ml. 
1400 mcg/14 ml = 1 0 0 mcg/ml. 
5. Working solution: 200 mcg/ml in final concentration. 
Pipette 2 mis of above solution #4 (20,000 mcg/ml) and further 
dilute with 3 mis Owrens buffer to get a concentration of 
8000 mcg/ml. 
Pipette 0.35 ml and add to PRP to make a final concentration 
of 200 mcg/ml. 
2800 mcg/14 ml = 200 mcg/ml. 
6. Working solution: 1000 mcg/ml in final concentration. 
Weigh* 315 mg of powder and dilute to 10 mis with Owrens 
buffer to get a concentration of 28,000 mcg/ml. 
Pipette 0.5 ml and add to PRP to make a final concentration 
of 1000 mcg/ml. 
14,000 mcg/14 ml = 1000 mcg/ml. 
* All weights were measured with a Mettler Balance, Mettler Instrument 
Corp., Hightstown, N.J., Model H51AR. 
APPENDIX V 
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PREPARATION OF THE AGGREGATING AGENTS 
1. Adenosine diphosphate (ADP): (Equine muscle, sodium salt) (Sigma 
Laboratories, St. Louis, Missouri, Lot #870-7120). 
a. Stock ADP: 1 x 10 M (1 mM) is prepared according to anhydrous 
weight, purity, and number of water groups attached, which 
varies with each lot number. 
b. Working ADP Solutions: 
1) Strong ADP - 1 x 10"
3
 M. 
* 2) Weak ADP - 1 x 10"
4
 M - dilute 0.1 ml of stock solution 
with 0.9 ml of Owrens buffer. Mix. 
3) Weaker ADP 
* a) 1 x 10"
5
 M - dilute 0.1 ml of 1 x 10"
4
 M solution with 
0.9 ml of Owrens buffer. Mix. 
* b) 3 x 10"
6
 M - dilute 0.1 ml of 1 x 10"
5
 M solution with 
0.23 ml of Owrens buffer, Mix. 
* Concentrations to be used. 
2. Epinephrine: (Parke Davis, Detroit, Michigan, Lot #7E356). 
a. Stock Solution: 1 mg/ml of a manufactured solution. 
b. Working Solution: 
1) Strong epinephrine - 1 x 10 M - dilute 1 ml of stock 
epinephrine solution with 4.45 ml of deionized water. Mix. 
Use a tuberculin syringe to measure. 
2) Weak epinephrine - 1 x 10'
4
 M - dilute 0.1 ml of 1 x 10"
3
 M 
with 0.9 ml of deionized water. Mix. 
3) Weaker epinephrine - 1 x 10"
5
 - dilute with 0.1 ml of 
1 x 1 0
- 4
 M with 0.9 ml of deionized water. Mix. 
46 
3. Collagen: (Sigma Laboratories, St. Louis, Missouri, 
Lot #10808010} 
a. Stock Collagen: 0.25 gm of dried collagen (bovine achilles 
tendon) is homogenized in 25 ml of 8.35 mM^acetic acid at 
4° C in a semi micro-container for a Waring® blender 
(Waring Products Corp., Winsted, Conn.). Homogenize for 
30 seconds at 20,000 rpm at 4° C. Add 25 ml cold distilled 
water and homogenize for another 30 seconds. Dilute with 
200 ml of cold 0.67 mM acetic acid. Store in 2 ml aliquots 
at -70° C. 
b. Standard Curve: Grind solution until it is almost homogenous. 
Pour collagen through four layers of 4 x 4 gauze squares into 
a 17 x 100 mm plastic tube and place on ice. Prepare serial 
dilutions of collagen using 1.67 mM acetic acid as a diluent. 
Establish a standard curve; this should be done when the 
stock collagen is prepared. 
c. Working Collagen: Immediately before use thaw 2-3 tubes of 
stock collagen and pour into a tissue grinder. Grind 
solution until it is almost homogenous. Pour collagen 
through four layers of 4 x 4 gauze squares into a 17 x 100 mm 
plastic tube and place on ice. Prepare serial dilutions to 
duplicate those used in establishing the standard curve. 
(See (b) above.) 
47 
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